

Date: 11/12/2025

To,

BSE Limited,  
Dept. of Corporate Services,  
Floor 25, PJ Towers,  
Dalal Street,  
Mumbai- 400001.

**Scrip Code: 526445**

Dear Sir/ Madam

**Subject: Outcome of the Board Meeting.**

**Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to our intimation letter dated December 5, 2025 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Thursday, December 11, 2025, the Directors have inter-alia, recorded the following:

- The approval of Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter and half year ended September 30, 2025, as recommended by the Audit Committee at their Meeting held today, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion (Annexure – 1).
- The resignation of Ms. Lakshmiprabha Kasiraman (DIN: 02885912) from the Position of Director on the Board has been taken note (Annexure – 2 & 3).
- The approval of reconstitution of Nomination & Remuneration Committee (Annexure – 4).
- The approval of reconstitution of Stakeholders and Relationship Committee (Annexure – 5).

The Board also took note of the non-compliance identified by BSE relating to Regulation 6(1) and the subsequent fine levied by the Exchange. Since the Compliance Officer was eventually appointed, though with a delay, the said regulation was thus complied with the fine was paid to BSE (Annexure 6).

We have attached herewith the copy of the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2025 along with the Limited Review Report for the said period.

The Board Meeting commenced at 4:30 P.M. and concluded at 7:00 P.M. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website <https://indrayani.com/> and also on BSE website <https://www.bseindia.com/stock-share-price/indrayani-biotech-ltd/indranib/526445/>.

Kindly take the same on records.

Thanking You  
Yours Faithfully

**For Indrayani Biotech Limited**

**Ramya Ravi**  
**Company Secretary and Compliance Officer**



## Annexure - 1

**VENKATESH & CO**  
Chartered Accountants

**Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015**

To  
The Board of Directors  
**Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30<sup>th</sup> September, 2025** and for the period from 1<sup>st</sup> July 2025 to 30<sup>th</sup> September 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30<sup>th</sup> September, 2024 and corresponding period from 1<sup>st</sup> July 2024 to 30<sup>th</sup> September 2024 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the entities mentioned in the Annexure - I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com



**VENKATESH & CO**  
Chartered Accountants

Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **7 Subsidiaries and 2 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30<sup>th</sup> September, 2025 reflects total revenues of ₹ **5,333.14 Lakhs**, total comprehensive profit / (loss) of ₹ **47.25 Lakhs** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

**for Venkatesh & Co**

Chartered Accountants

FRN : 0046365



**CA Dasaraty V**

Partner

M No : 026336

UDIN: **25026336BMINGW7503**

Chennai, 11<sup>th</sup> December 2025



**Annexure I to the Audit Report**

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	Dindigul Farm Product Limited*	Subsidiary
6	Matrix Boilers Private Limited	Subsidiary
7	IBL Investments Limited	Subsidiary
8	IBL Social Foundation	Subsidiary
9	Kniss Laboratories Private Limited	Step Down Subsidiary

**\*Consolidation Comprises of Financial results of Dindigul Farm Product Limited by the virtue of Control established over Board of Directors and decisions of management.**





**VENKATESH & CO**  
Chartered Accountants

**Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors,  
**Indrayani Biotech Limited**


We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter and period ended 30<sup>th</sup> September 2025. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**for Venkatesh & Co**  
Chartered Accountants

FRN : 0046865

  
CA Dasaraty V



Partner

M No : 026336

UDIN: **25026336BMINGV7016**

Chennai, 11<sup>TH</sup> December 2025

---

"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: [audit@venkateshandco.com](mailto:audit@venkateshandco.com)

**M/s. INDRAYANI BIOTECH LIMITED**

**CIN : L40100TN1992PLC129301**

**BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA**

**Consolidated Balance sheet as on 30th September 2025**

			Rs. In Lakhs	
Particulars	Note	As at 30 Sept 2025	As at 31 Mar 2025	
<b>ASSETS</b>				
<b>NON-CURRENT ASSETS</b>				
Property, plant and equipment	3	3,904.71	3,433.50	
Capital Work in Progress	4	2,290.17	2,566.94	
Goodwill	3	2,334.73	2,334.73	
Other Intangible assets			0.08	
<b>Financial assets</b>				
(i) Investments	5	28.13	24.78	
(ii) Other financial assets	6	347.29	514.20	
Deferred Tax Asset		22.11	22.63	
<b>Non-current tax assets</b>	7-A	106.17	106.17	
<b>Other Non Current Assets</b>		20.00	20.00	
<b>Total non-current assets</b>		<b>9,053.30</b>	<b>9,023.03</b>	
<b>CURRENT ASSETS</b>				
Inventories	9	4,321.43	4,134.19	
<b>Financial assets</b>				
(i) Trade receivables	10	6,229.89	5,868.95	
(ii) Cash and cash equivalents	11	455.94	28.82	
(iii) Loans	8-C	2,553.80	856.22	
(iv) Other Financial Assets	8-A	241.74	2,621.13	
<b>Current Tax Assets (Net)</b>	7-B	245.45	204.06	
<b>Other current assets</b>	8-B	4,344.17	4,080.15	
<b>Total current assets</b>		<b>18,392.42</b>	<b>17,793.52</b>	
<b>TOTAL ASSETS</b>		<b>27,445.71</b>	<b>26,816.55</b>	
<b>EQUITY AND LIABILITIES</b>				
<b>EQUITY</b>				
Equity share capital	12A	4,553.63	4,553.63	
Other equity	12B	3,027.88	2,697.32	
NCI		2,800.19	2,740.65	
<b>Total equity</b>		<b>10,381.70</b>	<b>9,991.60</b>	
<b>NON-CURRENT LIABILITIES</b>				

Financial liabilities			
(i) Borrowings	13	10,093.20	6,541.52
(ii) Lease Liabilities	14A	-13.51	
Provisions		-	7.49
Deffered Tax liabilities	14C	27.57	27.57
<b>Total non-current liabilities</b>		<b>10,107.26</b>	<b>6,576.58</b>
<b>CURRENT LIABILITIES</b>			
Financial liabilities			
(i) Borrowings	15	4,538.55	7,165.72
(ii) Lease Liabilities	14B	-	
(iii) Trade payables		-	
Total outstanding dues to micro enterprises and small enterprises; and		832.12	
Total outstanding dues of creditors other than micro enterprises and small enterprises		869.74	2,358.29
Other current liabilities	18	311.37	233.25
Provision	16	404.97	491.11
<b>Total current liabilities</b>		<b>6,956.75</b>	<b>10248.37</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>27,445.71</b>	<b>26816.55</b>



*Handwritten signature*

**INDRAYANI BIOTECH LIMITED**  
CIN: L40100TN1992PLC125301  
BLOCK 1, MODULE NO. 32 & 33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX,  
THIRU VI KA INDUSTRIAL ESTATE, GUINDYCHENNAI - 600032

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025**

(₹ in INR 'Lakhs except per share data)

S.No	Particulars	3 months ended	3 months ended	3 months ended	Year to date for	Year to date for	Previous year
		30-Sep-2025	30-June-2025	30-Sep-2024	period ended	period ended	ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations	3,594.85	2,910.37	3,081.31	6,505.22	6,234.09	13,022.84
2	Other Income	180.13	105.62	30.13	285.75	34.56	312.58
3	<b>Total Income (1+2)</b>	<b>3,774.98</b>	<b>3,015.99</b>	<b>3,111.44</b>	<b>6,790.97</b>	<b>6,268.65</b>	<b>13,335.42</b>
4	Expenses						
	(a) Cost of Materials consumed	2,193.93	2,075.82	1,487.17	4,269.74	3,245.50	8,277.21
	(b) Employee benefits expenses	397.47	289.23	513.94	666.70	1,085.89	2,046.78
	(c) Finance Costs	188.77	217.08	141.60	405.85	366.47	1,176.27
	(d) Depreciation and amortisation expense	130.03	85.82	279.46	215.85	362.20	336.81
	(e) Other expenses	758.74	347.17	569.44	1,105.91	994.29	2,072.70
5	<b>Total Expenditure excluding provisions and contingencies</b>	<b>3,668.94</b>	<b>2,915.12</b>	<b>2,991.61</b>	<b>6,664.06</b>	<b>6,654.35</b>	<b>13,909.77</b>
6	Operating Profit before Provisions and Contingencies (3-5)	106.04	20.87	119.84	126.91	214.30	(574.35)
7	Provisions (other than tax) and Contingencies						
8	Exceptional Items						
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (6-7-8)	106.04	20.87	119.84	126.91	214.30	-574.35
10	Tax expense	14.63	5.22	-1.85	20.05	7.6	36.4
11	Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9-10)	91.21	15.65	121.69	106.86	206.70	-610.75
12	Other Comprehensive Income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(2.61)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive income for the period attributable to	-	-	-	-	-	(613.36)
	Comprehensive income for the period attributable to the owners of the Company	40.13	10.24	61.20	47.33	105.10	(158.27)
	Total Comprehensive income for the period attributable to the non-controlling interest	51.08	5.41	60.48	59.54	101.59	(455.09)
13	Paid-up equity share capital (Rs.10 being the Face Value per share)	4553.63	4553.63	4553.63	4553.63	4553.63	4553.63
14	Reserves excluding Revaluation Reserves (as per balance sheet of previous accounting year)	-	-	-	-	-	-
15	Analytical Ratios						
(i)	Earnings Per Share (EPS)						
	- Basic	0.09	0.03	0.13	0.10	0.02	-0.35
	- Diluted	0.09	0.03	0.13	0.10	0.02	-0.35
16	NPA Ratios						
(a)	Gross/Net NPA	-	-	-	-	-	-
(b)	% of Gross/Net NPA	-	-	-	-	-	-
(c)	Return on Assets	-	-	-	-	-	-

**Notes:**


1. The above standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 11th December 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website [www.indrayani.com](http://www.indrayani.com)

3. Previous period figures have been regrouped wherever necessary.

4. There is no investor complaint received during the Quarter

For Indrayani Biotech Limited



Swaminathan Govindarajan  
Whole-time Director  
DIN : 02481041

<b>INDRAYANI BIOTECH LIMITED</b>		
<b>CIN : L40100TN1992PLC129301</b>		
<b>BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032</b>		
<b>Consolidated Cash Flow Statement for the half year ended 30/09/2025</b>		<b>Rs. In Lakhs</b>
<b>Particulars</b>	<b>As on 30-Sept-25</b>	<b>As on 31-Mar-25</b>
<b>Cash Flows From Operating Activities:-</b>		
Net Profit after Taxation	106.87	(610.75)
<b>Adjustment for Non cash Items</b>		
Add : Impairment/ Write off of Property Plant and Equipment and Capital Work in Progress		-
Add : Depreciation	215.85	336.81
Less : Interest Income Notional (As per Ind AS 109)		(2.17)
Less : Notional Income		2.52
Less: Share of profit of Associates		30.15
Other Comprehensive Income		-
Add: Interest Expenses Notional as per applicable IndAS		(2.61)
<b>Adjustment for Non Operating activities</b>		
Add : Interest Paid ( Including Interest on Lease Liabilities)	405.85	1,176.27
Less : Interest Income		63.34
	<b>728.57</b>	<b>993.56</b>
<b>Cash Flow Before Working Capital changes:-</b>		
Decrease (Increase) in Inventories	(187.24)	100.86
Decrease (Increase) in Trade receivables	(360.94)	(1,916.06)
Decrease (Increase) in Current Tax Assets	(41.39)	(171.44)
Decrease (Increase) in Other Financial Assets	2,550.98	345.84
Decrease (Increase) in other current assets	(264.02)	(1,684.50)
(Decrease) Increase in Short term borrowings	(2,655.99)	3,059.02
(Decrease) Increase in Financial liabilities		(96.21)
(Decrease) Increase in Trade payables	(656.43)	(1,380.75)
(Decrease) Increase in Other Current liabilities	78.12	(43.63)
(Decrease) Increase in Loans		
(Decrease) Increase in Provisions	(86.14)	2.71
<b>Cash Flow Before Tax and Extraordinary Items:-</b>		
Income Taxes Paid	20.05	116.40
	<b>-874.43</b>	<b>-674.18</b>
<b>Net Cash Flow From Operating Activities</b>		
<b>Cash Flow from Investing Activities:-</b>		
Less : Purchase of Capital Assets	(410.28)	(137.56)
Less : Increase / Decrease in Advances for Capital Expenditure		1,737.10
Add : Goodwill on Consolidation	-	
Less : Purchase of Investments	(3.35)	(2.45)
Less : Sale of Capital Assets		746.74
Add : Amount of Interest Received		63.34
Decrease (Increase) in Loans and advances & Other assets	(334.93)	67.16
	<b>-748.56</b>	<b>2,474.33</b>
<b>Net Cash flow used in Investing Activities</b>		
<b>Cash Flow from Financing Activities:-</b>		
Increase in Borrowings	2,455.95	(118.13)
Interest Income Notional (As per Ind AS 109)		2.17
Interest expense( Including Interest on Lease Liabilities)	-405.85	
Repayment of Lease Liabilities		-406.70
Increase in NCI		-2,365.02
Security Premium Received		
Interest Expenses Paid		1,176.27
Decrease in borrowings		(118.13)
	<b>2,050.11</b>	<b>-1,829.54</b>
<b>Net Cash Flow From Financing Activities</b>		
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>		
(Opening Balance)	28.82	58.21
Net Cash Flow during the year	427.12	-29.39
<b>(Closing Balance)</b>	<b>455.94</b>	<b>28.82</b>



Digitally signed by  
**SWAMINATHAN**  
**GOVINDARAJA**  
 N  
 Date: 2025.12.19  
 13:00:38 +05'30'

<b>M/s. INDRAYANI BIOTECH LIMITED</b>			
<b>CIN : L40100TN1992PLC129301</b>			
<b>BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL</b>			
<b>Standalone Balance sheet as on 30th September 2025</b>			
			<b>Rs. In Lakhs</b>
<b>Particulars</b>	<b>Note</b>	<b>As at 30 Sept 2025</b>	<b>As at 31 Mar 2025</b>
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	3	1,244.67	1,282.52
Capital Work in Progress	4	1,809.07	1,809.07
Goodwill	3	383.53	383.53
<b>Financial assets</b>			
(i) Investments	5	961.35	961.40
(ii) Other financial assets	6	305.31	462.61
<b>Non-current tax assets</b>	7-A	106.17	106.17
<b>Other Non Current Assets</b>		-	-
<b>Total non-current assets</b>		<b>4,810.09</b>	<b>5,005.30</b>
<b>CURRENT ASSETS</b>			
Inventories	9	166.80	168.60
<b>Financial assets</b>			
(i) Trade receivables	10	1,669.38	1,645.91
(ii) Cash and cash equivalents	11	6.35	6.21
(iii) Loans	8-C	4,780.89	4,624.30
(iv) Other Financial Assets	8-A	192.78	392.25
<b>Current Tax Assets (Net)</b>	7-B	213.67	189.49
<b>Other current assets</b>	8-B	1,043.84	1,035.71
<b>Total current assets</b>		<b>8,073.72</b>	<b>8,062.47</b>
<b>TOTAL ASSETS</b>		<b>12,883.81</b>	<b>13,067.77</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity share capital	12A	4,553.63	4,553.63
Other equity	12B	1,059.19	979.52
<b>Total equity</b>		<b>5,612.82</b>	<b>5,533.15</b>
<b>NON-CURRENT LIABILITIES</b>			
<b>Financial liabilities</b>			
(i) Borrowings	13	2,600.39	1,364.13
(ii) Lease Liabilities	14A	-	-
Deffered Tax liabilities	14C	22.38	22.38
<b>Total non-current liabilities</b>		<b>2,622.77</b>	<b>1,386.51</b>
<b>CURRENT LIABILITIES</b>			
<b>Financial liabilities</b>			
(i) Borrowings	15	4,043.82	4,801.97
(ii) Lease Liabilities	14B	-	-
(iii) Trade payables		-	-
Total outstanding dues to micro enterprises and small enterprises; and		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	17	190.72	855.67
Other current liabilities	18	85.06	99.92
Provision	16	328.63	390.55
<b>Total current liabilities</b>		<b>4,648.23</b>	<b>6,148.11</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>12,883.82</b>	<b>13,067.77</b>



*[Handwritten Signature]*

INDRAYANI BIOTECH LIMITED  
CIN: L40100TN1992PLC129301

BLOCK 1, MODULE NO.32 & 33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX,  
THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025

(₹ in INR 'Lakhs except per share data)

S.No	Particulars	3 months ended	3 months ended	3 months ended	Year to date for	Year to date for	Previous year
		30-Sep-2025	30-June-2025	30-Sep-2024	period ended	period ended	ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Adjusted
1	Income from Operations	593.13	668.57	950.69	1,261.70	2,019.78	3,776.91
2	Other Income	182.37	89.16	89.38	271.53	191.98	351.60
3	<b>Total Income (1+2)</b>	<b>775.49</b>	<b>757.73</b>	<b>1,040.07</b>	<b>1,533.22</b>	<b>2,211.76</b>	<b>4,128.51</b>
4	Expenses						
	(a) Cost of Materials consumed	305.98	335.28	379.96	641.24	854.48	1,478.43
	(b) Employee benefits expenses	155.56	150.15	320.38	305.71	723.96	1,323.68
	(c) Finance Costs	99.22	131.93	188.52	231.15	340.15	732.10
	(d) Depreciation and amortisation expense	16.51	15.25	31.76	31.76	63.74	102.49
	(e) Other expenses	135.60	108.09	106.29	243.61	199.22	427.18
5	<b>Total Expenditure excluding provisions and contingencies</b>	<b>712.87</b>	<b>740.70</b>	<b>1,026.91</b>	<b>1,453.57</b>	<b>2,191.55</b>	<b>4,063.88</b>
6	Operating Profit before Provisions and Contingencies (3-5)						
7	Provisions (other than tax) and Contingencies						
8	Exceptional Items						
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (6-7-8)	62.62	17.03	13.16	79.65	30.21	64.63
10	Tax expense	15.79	4.26	3.27	20.05	7.6	-80
11	<b>Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>46.83</b>	<b>12.77</b>	<b>9.89</b>	<b>59.60</b>	<b>22.61</b>	<b>144.63</b>
12	Other Comprehensive Income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive Income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of the Company	46.83	12.77	9.89	59.60	22.61	144.63
	Total Comprehensive Income for the period attributable to the non-controlling interest	-	-	-	-	-	-
13	Paid-up equity share capital (Rs.10 being the Face Value per share)	4553.63	4553.63	4553.63	4553.63	4553.63	4553.63
14	Reserves excluding Revaluation Reserves (as per balance sheet of previous accounting year)	-	-	-	-	-	-
15	Analytical Ratios						
(i)	Earnings Per Share (EPS)						
	- Basic	0.10	0.03	0.02	0.13	0.05	0.32
	- Diluted	0.10	0.03	0.02	0.13	0.05	0.32
16	NPA Ratios						
(a)	Gross/Net NPA	-	-	-	-	-	-
(b)	% of Gross/Net NPA	-	-	-	-	-	-
(c)	Return on Assets	-	-	-	-	-	-

Notes:


1. The above standalone financial results were reviewed and recommended by the audit Committee and approved by the Board of Directors at their meeting held on 11th December 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website www.indrayani.com

3. Previous period figures have been regrouped wherever necessary.

4. There is no investor complaint received during the quarter

For Indrayani Biotech Limited




Swaminathan Govindarajan  
Whole-time Director  
DIN : 02481041

## M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032

Standalone Cash Flow Statement for the half year ended 30/09/2025		Rs. In Lakhs	
Particulars	As on 30-Sept-25	As on 31-Mar-25	
<b>Cash Flows From Operating Activities:-</b>			
Net Profit after Taxation	59.60	64.63	
<b>Adjustment for Non cash items</b>			
Add : Impairment/ Write off of Property Plant and Equipment and Capital Work in Progress		-	
Add : Depreciation	31.76	102.49	
Less : Interest Income Notional (As per Ind AS 109)			
Less : Notional Income		(9.72)	
Add: Interest Expenses Notional as per applicable IndAS			
<b>Adjustment for Non Operating activities</b>			
Add : Interest Paid ( Including Interest on Lease Liabilities)	231.15	732.10	
Less : Interest income		-	
<b>Cash Flow Before Working Capital changes:-</b>	<b>322.51</b>	<b>889.50</b>	
Decrease (Increase) in Inventories	1.80	23.72	
Decrease (Increase) in Trade receivables	(23.47)	113.72	
Decrease (Increase) in Current Tax Assets	(24.18)	(53.44)	
Decrease (Increase) in Other Financial Assets	199.47	(52.35)	
Decrease (Increase) in other current assets	(8.13)	(261.02)	
(Decrease) Increase in Short term borrowings	(758.15)	430.14	
(Decrease) Increase in Financial liabilities			
(Decrease) Increase in Trade payables	(664.95)	583.33	
(Decrease) Increase in Other Current liabilities	(14.86)	(38.44)	
(Decrease) Increase in Provisions	(61.92)	100.17	
<b>Cash Flow Before Tax and Extraordinary Items:-</b>			
Income Taxes Paid	20.05	-	
<b>Net Cash Flow From Operating Activities</b>	<b>-1,011.84</b>	<b>1,735.34</b>	
<b>Cash Flow from Investing Activities:-</b>			
Less : Purchase of Capital Assets	6.09	(85.07)	
Less : Purchase of Investments	0.05	(5.59)	
Add : Rental Receipts		-	
Add : Amount of Interest Received		-	
Less : Sale of Capital Assets		-	
Decrease (Increase) in Loans and advances & Other assets	157.31	(43.09)	
<b>Net Cash flow used in Investing Activities</b>	<b>163.45</b>	<b>-133.75</b>	
<b>Cash Flow from Financing Activities:-</b>			
Increase in Borrowings	1,236.26	(123.82)	
Interest Income Notional (As per Ind AS 109)			
Increase in Share capital		-	
Issue of Share Warrant		-63.06	
Interest expense( Including Interest on Lease Liabilities)	-231.15	-732.10	
Repayment of Lease Liabilities			
Loan to Group Companies	-156.59	-702.71	
Security Premium Received			
Issue Expenses Paid			
Decrease in borrowings			
<b>Net Cash Flow From Financing Activities</b>	<b>848.53</b>	<b>-1,621.67</b>	
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>			
(Opening Balance)	6.21	26.29	
Net Cash Flow during the year	0.14	-20.08	
<b>(Closing Balance)</b>	<b>6.35</b>	<b>6.21</b>	



**Annexure - 2**

**Additional Details as required under SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, Regulation 30 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Resignation of Ms. Lakshmiprabha Kasiraman (DIN: 02885912) from the Position of Director on the Board.**

<b>S.No</b>	<b>Particulars</b>	<b>Details</b>
1	Name	Ms. Lakshmiprabha Kasiraman
2	DIN	02885912
3	Designation	Non-executive and Non-Independent Director
4	Reason for change viz. Appointment-resignation, removal, death or otherwise;	Resignation from the position of Director on the Board of the Company due to personal reasons.
5	Date of appointment/ cessation (as applicable) & terms of appointment.	13.11.2025
6	Detailed Reason for Resignation.	Personal commitments
7	Date of Cessation / Effective Date of Resignation.	13.11.2025
8	Confirmation from Director	The director has confirmed that there are no other material reasons for resignation other than those provided above.
9	Acknowledgment by the Board.	The Board placed on record its sincere appreciation for the valuable contribution, guidance, and support extended by Ms. Lakshmiprabha Kasiraman during her tenure as Director and conveyed best wishes for her future endeavours.

# Annexure - 3

From

K.Lakshmi Prabha  
Director  
Indrayani Biotech Limited  
Chennai

To

The Board of Directors  
Indrayani Biotech Limited  
Module 32,33, Block-1,  
SIDCO ELECTRONICS COMPLEX, 3rd Phase,  
Thiru Vi Ka Industrial Estate, SIDCO Industrial Estate,  
Guindy, Chennai, Tamil Nadu 600032

Subject: Resignation from the Directorship of Indrayani Biotech Limited

Ref: Date of Appointment : 20 08 2018 , as Director


Dear Members of the Board,

I hereby tender my resignation from the position of Director  
of Indrayani Biotech Limited with immediate effect.

Kindly acknowledge this letter and take the necessary steps to inform the relevant  
statutory authorities and stakeholders as required.

Thank you once again for your support and understanding.

Yours sincerely,



K Lakshmi Prabha  
DIN: 02885912


Chennai

13 NOV 2025

(9841199326 / lakshmi Prabha@gmail.com)

Received

14/11/2025



#### Annexure - 4

**Additional Details as required under Regulation 30, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Reconstitution of the Nomination and Remuneration Committee due to resignation of Ms. Lakshmiprabha Kasiraman. Post reconstitution, the composition of the Nomination and Remuneration Committee is as under:

<b>Sr. No.</b>	<b>Name of the Member</b>	<b>Designation in the Committee</b>	<b>Nature of Directorship</b>
1	Dr. Bokara Nagarajan Padmaja Priyadarshini	Chairperson	Independent Director
2	Mr. Kannimangalam Subramanyan Vaidyanathan	Member	Independent Director
3	Mr. Nangavaram Mahadevan Ranganathan	Member	Independent Director

### Annexure - 5

**Additional Details as required under Regulation 30, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and other relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Reconstitution of the Stakeholders Relationship Committee due to resignation of Ms. Lakshmiprabha Kasiraman. Post reconstitution, the composition of the Stakeholders Relationship Committee is as under:

<b>Sr. No.</b>	<b>Name of the Member</b>	<b>Designation in the Committee</b>	<b>Nature of Directorship</b>
1	Mr. Nangavaram Mahadevan Ranganathan	Chairperson	Independent Director
2	Mr. Kannimangalam Subramanyan Vaidyanathan	Member	Independent Director
3	Dr. Bokara Nagarajan Padmaja Priyadarshini	Member	Independent Director

## 526445-Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance)

From: bse.soplodr <bse.soplodr@bseindia.com>  
 To: info@indrayani.com <info@indrayani.com>, indrayanichennai@gmail.com <indrayanichennai@gmail.com>, info@indrayani.com <info@indrayani.com>, CS@INDRAYANI.COM <CS@INDRAYANI.COM>  
 Cc: bse.soplodr <bse.soplodr@bseindia.com>  
 Date: 20/11/2025 04:50 PM

Ref.: SOP-CReview/ QTR-Sep25/20.11.2025

To

The Company Secretary/Compliance Officer

Company Name: Indrayani Biotech Ltd

scrip Code: 526445

Dear Sir/Madam,

Sub: Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance).

The company is advised to refer to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued by Securities and Exchange Board of India (SEBI) with respect to penal actions prescribed for non-compliance of certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Standard Operating Procedure for suspension and revocation of trading of specified securities of listed entities.

The Exchange had also issued a guidance note regarding the provisions of the said SEBI circular which is disseminated on the Exchange website at the following link:

[https://www.bseindia.com/downloads1/Guidance\\_Note\\_for\\_SEBI\\_SOP\\_Circular.pdf](https://www.bseindia.com/downloads1/Guidance_Note_for_SEBI_SOP_Circular.pdf)

In this regard it is observed that the company is non-compliant/late compliant with the following Regulations for the period mentioned below:

Applicable Regulation of SEBI (LODR) Regulations, 2015	Fine prescribed	Fines levied for the	Compliance status	Fine payable by the company as on November 20, 2025		
				Basic Fine	GST @ 18 %	Total Fine payable
Regulation 13(3) Non-submission of the statement on shareholder complaints within the period prescribed under this regulation or under any circular issued in respect of redressal of investor grievances	*Rs. 1,000/- per day till the date of compliance.	quarter ended September 2025	-	0	0	0
Regulation 76 of SEBI (Depositories & Participants) Regulation 2018 Non-submission of Reconciliation of share Capital audit report.	NA	quarter ended September 2025	-			

<b>Regulation 6(1)</b>  Non-compliance with requirement to appoint a qualified company secretary as the compliance officer.	Rs. 1,000 per day	quarter ended September 2025	Delayed complied	14000	2520	16520
<b>Regulation 7(1)</b>  Non-compliance with requirement to appoint share transfer agent	Rs. 1,000 per day	quarter ended September 2025		0	0	0
		<b>Total</b>		<b>14000</b>	<b>2520</b>	<b>16520</b>

(\* ) As per the provisions of the circular the fines will continue to be computed further till the time of rectification of the non-compliance to the satisfaction of the Exchange or till the scrip of the listed entity is suspended from trading for non-compliance with aforesaid provisions.

The Company is therefore advised to note that as per the provisions of this circular:

- The company is required to ensure compliance with above regulation and ensure to pay the aforesaid fines including GST within 15 days from the date of this letter/email, failing which Exchange shall, pursuant to the provisions of the aforesaid circular, initiate action related to freezing of the entire shareholding of the promoter in this entity as well as all other securities held in the demat account of the promoter. The company is advised to bring the provisions of this Circular to the notice of the promoter of the company. In this regard, it may also be noted that details of outstanding fines payable pursuant to SEBI SOP Circulars for the prior period, if any, will be provided separately. The SEBI circular stipulates that the freeze on promoter demat accounts should be lifted only after the company complies and pays all the outstanding fines.
- Further in the event of this being the second consecutive quarter of non-compliance for the Regulation 76 would result in the company being transferred to 2 group and liable for suspension of trading of its equity shares.
- The company is also advised to ensure that the subject matter of non-compliance which has been identified and indicated by the Exchange and any subsequent action taken by the Exchange in this regard shall be placed before the Board of Directors of the company in its next meeting. Comments made by the board shall be duly informed to the Exchange for dissemination.

Yours faithfully

Reena Raphael

Manager

Listing Compliance & Operations

Arpeeta Pawaskar

Deputy Manager

Listing Compliance & Operations

In case of any further queries / clarifications please email the following ids:

Regulation	Officer Name	Email Id
Reg. 6, 7 & 76	Ms. Arpeeta Pawaskar	Arpeeta.Pawaskar@bseindia.com bse.sopldr@bseindia.com
Reg.13(3)	Mr. Krishna Rathi	Krishna.Rathi@bseindia.com bse.sopldr@bseindia.com

Company is requested to remit the fine amount to the following designated **VIRTUAL BANK ACCOUNT** of the Exchange:

Company Name	Indrayani Biotech Ltd		
Account Name	Bank Name & Branch	Virtual Bank Account No.†	IFSC Code
BSE Limited	ICICI Bank Ltd.- CMS Branch	BSER04842	ICIC000C104

**\*Note: This bank account is specifically dedicated to SOP fines and waiver fees only. Therefore, company is advised not to deposit/credit any amount payable other than SOP fines/penalties/waiver fees.**

The company is required to submit fine remittance details in the following format given at Annexure I to Email id: [bse.sop@bseindia.com](mailto:bse.sop@bseindia.com)

**Annexure-I (On letterhead of the company)**

Sub: Details of Payment of fines for Non-Compliance with Regulations of SEBI (LODR) Regulations, 2015.

**Remittance details:**

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid	TDS deducted, if any	Net Amount paid

This mail is classified as [PUB] by reena.reghel on November 20, 2025 at 15:50:13.

**Sub: Details of Payment of fines for Non-Compliance with Regulations of SEBI (LODR) Regulations, 2015.**

**From** IBL COMPANY SECRETARY <cs@indrayani.com>  
**To** <bse.soplodr@bseindia.com>  
**Date** 05/12/2025 03:57 PM

 Annexure I.pdf (~134 KB)

Dear Sir/ Ma'am,

We wish to inform you that the Company has paid the fines imposed by the Stock Exchange for non-compliance under **6(1)** of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with the compliance requirements, we are submitting herewith the **details of payment of fine**, duly compiled and attached as **Annexure-I** for your kind perusal and records.

-

**For Indrayani Biotech Limited**  
Secretarial team